Results of HCV screening of volunteer blood donors with a chemiluminescent immunoassay and a second- or third-generation EIA: Overlap of false-positive reactivity and its impact on donor management

Transfusion

Volumn 40, Issue 5, 2000, Pages 580-584

  Kiely, Philip ^a   Wilson, D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C ANTIBODY;

ARTICLE; BLOOD DONOR; CHEMOLUMINESCENCE; HEPATITIS C; HUMAN; IMMUNOASSAY; LABORATORY DIAGNOSIS; SCREENING TEST;

BLOOD DONORS; CHEMILUMINESCENT MEASUREMENTS; FALSE POSITIVE REACTIONS; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; IMMUNOASSAY; IMMUNOENZYME TECHNIQUES; MASS SCREENING; RNA, VIRAL;

EID: 0034031620     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2000.40050580.x     Document Type: Article

References (17)

1. Sakugawa H, Nakasone H, Nakayoshi T, et al. High proportion of false positive reactions among donors with anti-HCV antibodies in a low prevalence area. J Med Virol 1995;46:334-8.
2. McLindon JP, Paver WK, Babbs C, et al. Hepatitis C-related chronic liver disease among asymptomatic blood donors in the north west of England. J Infect 1995;30:253-9.
3. Allain JP, Kitchen A, Aloysius S, et al. Safety and efficacy of hepatitis C virus antibody screening of blood donors with two sequential screening assays. Transfusion 1996;36:401-5.
4. Bar-Shany S, Green MS, Shinar E. False positive tests for anti-hepatitis C antibodies and the problem of notifying blood donors. Int J Epidemiol 1996;25:674-8.
5. Dow BC, Buchanan I, Munro H, et al. Relevance of RIBA-3 supplementary test to HCV PCR positivity and genotypes for HCV confirmation of blood donors. J Med Virol 1996;49:132-6.
6. Ownby HE, Korelitz JJ, Busch MP, et al. Loss of volunteer blood donors because of unconfirmed enzyme immunoassay screening results. Retrovirus Epidemiology Donor Study. Transfusion 1997;37:199-205.
7. Kolho E, Farkkila M, Makinen J, et al. Clinical significance of hepatitis C antibodies in blood donors. J Med Virol 1994;43:129-34.
8. Alonso C, Pedroso ML, De Sanjose S, et al. Hepatitis C virus among blood donors: follow-up study. Transfusion 1994;34:527-30.
9. Schneeberger P, van der Nat H, van Dijk W, et al. Diagnosis of hepatitis C virus infection using two second-generation enzyme immunoassays with a recombinant immunoblot assay for confirmation. Eur J Clin Microbiol Infect Dis 1994;13:118-21.
10. Lok AS, Gunaratnam NT. Diagnosis of hepatitis C. Hepatology 1997;26(3 Suppl 1):48S-56S.
11. A strategy for the detection and management of hepatitis C in Australia. National Health and Medical Research Council Working Party on Hepatitis C. Canberra: Australian Government Publishing Service, 1997.
12. Dhumeaux D, Doffoel M, Galmiche JP. A French consensus conference on hepatitis C: screening and treatment. J Hepatol 1997;27:941-4.
13. Pawlotsky JM, Lonjon I, Hezode C, et al. What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories? Hepatology 1998:27:1700-2.
14. Stephenson M, Kasatkina M, Dax EM. Testing strategy development in HCV serology (abstract). Presented at the Australian Society of Microbiology Annual Scientific Meeting, Melbourne, 28 September-3 October 1997:A86.
15. Gerken G, Pontisso P, Roggendorf M, et al. Clinical evaluation of a single reaction, diagnostic polymerase chain reaction assay for the detection of hepatitis C virus RNA. J Hepatol 1996:24:33-7.
16. Busch MP, Tobler L, Quan S, et al. A pattern of 5-1-1 and c100-3 only on hepatitis C virus (HCV) recombinant immunoblot assay does not reflect HCV infection in blood donors. Transfusion 1993;33:84-8.
17. Damen M, Zaaijer HL, Cuypers HTM, et al. Reliability of the third-generation recombinant immunoblot assay for hepatitis C virus. Transfusion 1995;35:745-9.